274 related articles for article (PubMed ID: 26284586)
21. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
22. Switch in signaling control of mTORC1 activity after oncoprotein expression in thyroid cancer cell lines.
Malaguarnera R; Chen KY; Kim TY; Dominguez JM; Voza F; Ouyang B; Vundavalli SK; Knauf JA; Fagin JA
J Clin Endocrinol Metab; 2014 Oct; 99(10):E1976-87. PubMed ID: 25029414
[TBL] [Abstract][Full Text] [Related]
23. Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways.
Gunda V; Bucur O; Varnau J; Vanden Borre P; Bernasconi MJ; Khosravi-Far R; Parangi S
Cell Death Dis; 2014 Mar; 5(3):e1104. PubMed ID: 24603332
[TBL] [Abstract][Full Text] [Related]
24. Obatoclax and LY3009120 Efficiently Overcome Vemurafenib Resistance in Differentiated Thyroid Cancer.
Wei WJ; Sun ZK; Shen CT; Song HJ; Zhang XY; Qiu ZL; Luo QY
Theranostics; 2017; 7(4):987-1001. PubMed ID: 28382170
[TBL] [Abstract][Full Text] [Related]
25. The BRAF-inhibitor PLX4720 inhibits CXCL8 secretion in BRAFV600E mutated and normal thyroid cells: a further anti-cancer effect of BRAF-inhibitors.
Coperchini F; Croce L; Denegri M; Awwad O; Ngnitejeu ST; Muzza M; Capelli V; Latrofa F; Persani L; Chiovato L; Rotondi M
Sci Rep; 2019 Mar; 9(1):4390. PubMed ID: 30867499
[TBL] [Abstract][Full Text] [Related]
26. Treatment of vemurafenib-resistant SKMEL-28 melanoma cells with paclitaxel.
Thang ND; Nghia PT; Kumasaka MY; Yajima I; Kato M
Asian Pac J Cancer Prev; 2015; 16(2):699-705. PubMed ID: 25684511
[TBL] [Abstract][Full Text] [Related]
27. MAPK- and AKT-activated thyroid cancers are sensitive to group I PAK inhibition.
Knippler CM; Saji M; Rajan N; Porter K; La Perle KMD; Ringel MD
Endocr Relat Cancer; 2019 Aug; 26(8):699-712. PubMed ID: 31146260
[TBL] [Abstract][Full Text] [Related]
28. Effects of metformin and pioglitazone combination on apoptosis and AMPK/mTOR signaling pathway in human anaplastic thyroid cancer cells.
Ozdemir Kutbay N; Biray Avci C; Sarer Yurekli B; Caliskan Kurt C; Shademan B; Gunduz C; Erdogan M
J Biochem Mol Toxicol; 2020 Oct; 34(10):e22547. PubMed ID: 32589349
[TBL] [Abstract][Full Text] [Related]
29. Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines.
Varmeh S; Vanden Borre P; Gunda V; Brauner E; Holm T; Wang Y; Sadreyev RI; Parangi S
Surgery; 2016 Jan; 159(1):152-62. PubMed ID: 26456124
[TBL] [Abstract][Full Text] [Related]
30. Rapamycin synergizes the cytotoxic effects of MEK inhibitor binimetinib and overcomes acquired resistance to therapy in melanoma cell lines in vitro.
Ryabaya OO; Abramov IS; Khochenkov DA; Akasov R; Sholina NV; Prokofieva AA
Invest New Drugs; 2021 Aug; 39(4):987-1000. PubMed ID: 33683500
[TBL] [Abstract][Full Text] [Related]
31. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J
Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
[TBL] [Abstract][Full Text] [Related]
32. Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells.
Klubo-Gwiezdzinska J; Jensen K; Costello J; Patel A; Hoperia V; Bauer A; Burman KD; Wartofsky L; Vasko V
Endocr Relat Cancer; 2012 Jun; 19(3):447-56. PubMed ID: 22389381
[TBL] [Abstract][Full Text] [Related]
33. B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells.
Roos WP; Quiros S; Krumm A; Merz S; Switzeny OJ; Christmann M; Loquai C; Kaina B
Oncotarget; 2014 Dec; 5(24):12607-20. PubMed ID: 25557167
[TBL] [Abstract][Full Text] [Related]
34. Hgf/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers.
Knauf JA; Luckett KA; Chen KY; Voza F; Socci ND; Ghossein R; Fagin JA
J Clin Invest; 2018 Aug; 128(9):4086-4097. PubMed ID: 29990309
[TBL] [Abstract][Full Text] [Related]
35. Tunicamycin induces paraptosis potentiated by inhibition of BRAFV600E in FRO anaplastic thyroid carcinoma cells.
Kim SH; Shin HY; Kim YS; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Anticancer Res; 2014 Sep; 34(9):4857-68. PubMed ID: 25202067
[TBL] [Abstract][Full Text] [Related]
36. Resveratrol Overcomes Cellular Resistance to Vemurafenib Through Dephosphorylation of AKT in BRAF-mutated Melanoma Cells.
Luo H; Umebayashi M; Doi K; Morisaki T; Shirasawa S; Tsunoda T
Anticancer Res; 2016 Jul; 36(7):3585-9. PubMed ID: 27354627
[TBL] [Abstract][Full Text] [Related]
37. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
Trunzer K; Pavlick AC; Schuchter L; Gonzalez R; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Kim KB; Weber JS; Hersey P; Long GV; Lawrence D; Ott PA; Amaravadi RK; Lewis KD; Puzanov I; Lo RS; Koehler A; Kockx M; Spleiss O; Schell-Steven A; Gilbert HN; Cockey L; Bollag G; Lee RJ; Joe AK; Sosman JA; Ribas A
J Clin Oncol; 2013 May; 31(14):1767-74. PubMed ID: 23569304
[TBL] [Abstract][Full Text] [Related]
38. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
Liu J; Zhang L; Zhang X; Xing X
J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
[TBL] [Abstract][Full Text] [Related]
39. The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors.
Delmas A; Cherier J; Pohorecka M; Medale-Giamarchi C; Meyer N; Casanova A; Sordet O; Lamant L; Savina A; Pradines A; Favre G
Oncotarget; 2015 Jun; 6(17):15250-64. PubMed ID: 26098773
[TBL] [Abstract][Full Text] [Related]
40. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
